These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer.
    Author: Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS.
    Journal: Menopause; 2013 Feb; 20(2):162-8. PubMed ID: 22990756.
    Abstract:
    OBJECTIVE: The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors. METHODS: A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire. RESULTS: In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitor-treated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns. CONCLUSIONS: Our findings suggest that sexual dysfunction in aromatase inhibitor-treated women is a greatly underestimated problem.
    [Abstract] [Full Text] [Related] [New Search]